These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 23883783

  • 1. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
    Patel MR, Jay-Dixon J, Sadiq AA, Jacobson BA, Kratzke RA.
    J Thorac Oncol; 2013 Sep; 8(9):1142-7. PubMed ID: 23883783
    [Abstract] [Full Text] [Related]

  • 2. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 3. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [Abstract] [Full Text] [Related]

  • 4. LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial-Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.
    Hu C, Zhou A, Hu X, Xiang Y, Huang M, Huang J, Yang D, Tang Y.
    Int J Mol Sci; 2022 Oct 31; 23(21):. PubMed ID: 36362025
    [Abstract] [Full Text] [Related]

  • 5. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.
    Lung Cancer; 2013 Sep 31; 81(3):354-361. PubMed ID: 23769318
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 31; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 9. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
    Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY.
    Cancer Biol Ther; 2012 Mar 31; 13(5):272-80. PubMed ID: 22236867
    [Abstract] [Full Text] [Related]

  • 10. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.
    Clin Exp Metastasis; 2008 Mar 31; 25(8):843-54. PubMed ID: 18696232
    [Abstract] [Full Text] [Related]

  • 11. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug 31; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
    Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.
    Mol Cancer Ther; 2012 Jan 31; 11(1):204-13. PubMed ID: 22075159
    [Abstract] [Full Text] [Related]

  • 15. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition.
    Madanayake TW, Welsh EA, Darville LNF, Koomen JM, Chalfant CE, Haura EB, Robinson TJ.
    Nucleic Acid Ther; 2022 Oct 02; 32(5):391-400. PubMed ID: 35861718
    [Abstract] [Full Text] [Related]

  • 17. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 02; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 18. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M, Takahashi T, Yamamoto N, Koh Y.
    J Thorac Oncol; 2013 Mar 02; 8(3):259-69. PubMed ID: 23334091
    [Abstract] [Full Text] [Related]

  • 19. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
    Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M, Puri N.
    PLoS One; 2013 Mar 02; 8(11):e78398. PubMed ID: 24223799
    [Abstract] [Full Text] [Related]

  • 20. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
    Osude C, Lin L, Patel M, Eckburg A, Berei J, Kuckovic A, Dube N, Rastogi A, Gautam S, Smith TJ, Sreenivassappa SB, Puri N.
    Cells; 2022 May 19; 11(10):. PubMed ID: 35626731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.